Lantern Pharma Inc. (NASDAQ: LTRN), a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced ...
Mobility in the UAE is becoming a fully connected ecosystem, where integration, intelligence, and seamless customer journeys ...
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ...
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at ...
Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, ...
Purpose Few studies have examined how psychosocial risk and protective factors in adolescence shape mental health outcomes ...
AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...
The survey found that about a third of parents read to their babies and toddlers weekly. Around 20% of parents said they ...
Genomics, Inc. , a leader in single cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through ...
AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, pos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback